NCT02062190View on ClinicalTrials.gov

Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

May 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

resveratrol

"100mg 2x/day~1 month"

Trial Locations (1)

90035-903

HCPA, Porto Alegre

All Listed Sponsors
collaborator

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

OTHER_GOV

lead

Federal University of Rio Grande do Sul

OTHER

NCT02062190 - Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia | Biotech Hunter | Biotech Hunter